Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Nicholas Belviso

Showing results (21-30 of 24) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 24 results.
Neurology and Therapy|June 16, 2025
Comparative Effectiveness of Fumarates Versus Sphingosine-1-Phosphate Receptor Modulators in Black Patients with Multiple SclerosisSophia Woodson, Edward J Gettings, Chu-Yueh Guo, et al.
Advances in Therapy|February 18, 2026
Comparative Effectiveness and Risk of Severe Infection in Adult Patients With MS Treated With Diroximel Fumarate Versus Anti-CD20 Monoclonal Antibodies: A Real-World Claims AnalysisAhmed Z Obeidat, Michelle Betz, Rebecca Straus Farber, et al.
Neurology|April 22, 2024
Temporal Relationship Between Serum Neurofilament Light Chain and Radiologic Disease Activity in Patients With Multiple SclerosisRobert J Fox, Bruce A C Cree, Jérôme de Sèze, et al.
Multiple Sclerosis Journal - Experimental, Translational and Clinical|May 27, 2024
Comparative effectiveness of dimethyl fumarate versus non-specific immunosuppressants: Real-world evidence from MSBaseTim Spelman, Sara Eichau, Raed Alroughani, et al.
Pageof 3

Showing results (21-30 of 24) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 24 results.
Neurology and Therapy|June 16, 2025
Comparative Effectiveness of Fumarates Versus Sphingosine-1-Phosphate Receptor Modulators in Black Patients with Multiple SclerosisSophia Woodson, Edward J Gettings, Chu-Yueh Guo, et al.
Advances in Therapy|February 18, 2026
Comparative Effectiveness and Risk of Severe Infection in Adult Patients With MS Treated With Diroximel Fumarate Versus Anti-CD20 Monoclonal Antibodies: A Real-World Claims AnalysisAhmed Z Obeidat, Michelle Betz, Rebecca Straus Farber, et al.
Neurology|April 22, 2024
Temporal Relationship Between Serum Neurofilament Light Chain and Radiologic Disease Activity in Patients With Multiple SclerosisRobert J Fox, Bruce A C Cree, Jérôme de Sèze, et al.
Multiple Sclerosis Journal - Experimental, Translational and Clinical|May 27, 2024
Comparative effectiveness of dimethyl fumarate versus non-specific immunosuppressants: Real-world evidence from MSBaseTim Spelman, Sara Eichau, Raed Alroughani, et al.
Pageof 3